Subjects should not be vaccinated with live attenuated vaccines within one month prior to starting tremelimumab treatment
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Patients should not be vaccinated with live attenuated vaccines within 1 month of starting tremelimumab and durvalumab treatment; subjects, if enrolled, should not receive live vaccine during the study and 180 days after the last dose of both drugs
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of avelumab
Vaccinated with live, attenuated vaccines within 4 weeks of enrollment
Vaccinated with live, attenuated vaccine within 4 weeks or as recommended by the product manufacturer prior to the first dose, during treatment, or within 100 days of the last dose of JNJ-64407564
Vaccinated with live, attenuated vaccines within 4 weeks of enrollment
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.
Patients should not be vaccinated with live attenuated vaccines within 1 month of starting pembrolizumab treatment
Vaccinated with live, attenuated vaccine(s) within 28 days prior to first dose of study drug
Vaccinated with live, attenuated vaccine within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of enrollment
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of enrollment
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of enrollment
Patients should not be vaccinated with live attenuated vaccines within 30 days of starting durvalumab or tremelimumab treatment
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of randomization
Vaccinated with live, attenuated vaccines within 4 weeks of study entry
Subjects should not be vaccinated with live attenuated vaccines within one month prior to starting tremelimumab treatment
Vaccinated with live, attenuated vaccines within 4 weeks of initiation of therapy
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Patient has been vaccinated with live attenuated vaccines within 4 weeks before study vaccination
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of study entry
Vaccinated with any of the vaccines planned for administration in the trial within 8 weeks of starting treatment on the study
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Patients should not be vaccinated with live attenuated vaccines within 1 month of starting tremelimumab and/or durvalumab (MEDI4736) treatment
Vaccinated with live, attenuated vaccines within 4 weeks of the first dose of study drug
Vaccinated with live attenuated vaccines =< 4 weeks from starting study drugs
Subjects should not be vaccinated with live attenuated vaccines within one month prior to starting tremelimumab treatment
Vaccinated with live, attenuated vaccines within 4 weeks of study entry
Subjects that have been vaccinated with live, attenuated vaccines within 4 weeks of the first dose of study drug are not eligible
Patient must not be vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Patients should not be vaccinated with live attenuated vaccines within 1 month of starting tremelimumab treatment
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of initiation of therapy
Vaccinated with live, attenuated vaccines within 4 weeks of enrollment
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.
Vaccinated with live, attenuated vaccines with 4 weeks of first does of study drug
Vaccinated with live, attenuated vaccines =< 4 weeks prior to registration
Vaccinated with live, attenuated vaccines within 4 weeks of treatment
Vaccinated with live, attenuated vaccines within 4 weeks of starting ibrutinib
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within four weeks of the first dose of study drug
